ITM Isotope Technologies Munich SE

ITM Isotope Technologies Munich SE is a privately held biotechnology and radiopharmaceutical company dedicated to the development, production, and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes for use in cancer treatment. Founded in 2004, ITM has established GMP manufacturing and a robust global supply network of innovative, first-in-class medical radioisotopes and generator platforms for a new generation of targeted cancer diagnostics and therapies. They are developing a proprietary portfolio and growing Precision Oncology Pipeline of targeted treatments in various stages of clinical development, addressing a range of cancers such as neuroendocrine tumors, glioblastoma, prostate cancer, and bone metastases. Their lead candidate, n.c.a. 177Lu-edotreotide, is undergoing two international pivotal phase III clinical trials for the treatment of neuroendocrine tumors.

ITM's mission is to significantly improve treatment outcomes and quality of life for cancer patients while reducing side effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology. The company emphasizes diversity and inclusion in its workplace, recognizing the value of diverse perspectives and talents. ITM is also committed to ethical business practices and has established a Code of Conduct and Whistle Blowing Reporting system to ensure compliance with applicable laws and regulations.

ITM Isotope Technologies Munich SE offers a hybrid working model, allowing for remote-based or office-based work. This flexibility allows employees to choose a work environment that best suits their needs and preferences. The company also offers flexible working hours, further enhancing the work-life balance for their employees.

ITM offers a competitive benefits package designed to attract and retain employees. Benefits include a comprehensive onboarding program, flexible work hours, home office options, attractive special payments, an employee participation program, a job bike or subsidized job ticket, an above-average contribution to the company pension scheme, individually tailored further training programs (including German and English courses), and health promotion programs (e.g., subsidies for local fitness studios, sponsorship of sporting events, and various lifestyle coaching sessions).

ITM Isotope Technologies Munich SE is a privately owned biotechnology and radiopharmaceutical group of companies committed to developing, producing, and globally supplying targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes for use in cancer treatment. Their goal is to improve treatment outcomes and quality of life for cancer patients by offering innovative and precise solutions in Precision Oncology, ultimately aiming to give patients better answers than “maybe”.

ITM fosters a collaborative and respectful work environment that prioritizes teamwork, trust, and the well-being of its employees. They champion diversity and inclusion, recognizing that these values are essential for innovation and success. The company fosters a culture of openness and communication, where everyone feels valued and empowered to contribute to their shared mission of improving cancer treatments.

ITM Isotope Technologies Munich SE actively promotes diversity and inclusion, believing that a multi-cultural workplace drives innovation and allows them to develop precise solutions. They value their employees for their diverse perspectives, experiences, talents, and backgrounds, supporting an open and respectful culture that embraces differences in age, ethnicity, race, religion, gender, sexual orientation, disabilities, and social background. ITM is a signatory of the Charter for Diversity of Companies in Germany, a corporate initiative to promote diversity, and a member of the Fair Company Initiative, which focuses on providing fair working conditions and development prospects for young people.